Chapter 11  ·  Module 4

Ezetimibe and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Visual summary — mechanisms, drug comparison, and sequential add-on strategy

Ezetimibe — Mechanism and Role

Mechanism

Ezetimibe Blocks NPC1L1

  • Selectively inhibits Niemann-Pick C1-Like 1 transporter on intestinal brush border
  • Blocks absorption of dietary and biliary cholesterol
  • Reduces cholesterol delivery to liver
  • Triggers compensatory low-density lipoprotein receptor upregulation via SREBP-2
  • Does NOT affect triglyceride or vitamin absorption

Clinical profile

Ezetimibe at a Glance

  • Low-density lipoprotein reduction: 18–20% monotherapy; 18–25% added to statin
  • Oral, 10 mg once daily — fixed dose, no titration
  • No cytochrome P450 drug interactions
  • No hepatotoxicity, no diabetes risk, no muscle toxicity
  • Generic — low cost
  • Cardiovascular outcomes proven (post-acute coronary syndrome trial)

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors — Mechanism and Agents

Normal PCSK9 activity

Without Inhibitor

  • Proprotein convertase subtilisin/kexin type 9 binds low-density lipoprotein receptor at hepatocyte surface
  • Receptor directed to lysosomal degradation instead of recycling
  • Fewer receptors on cell surface
  • Higher plasma low-density lipoprotein cholesterol

Monoclonal antibodies

Evolocumab / Alirocumab

  • Block proprotein convertase subtilisin/kexin type 9 in bloodstream
  • Low-density lipoprotein receptor recycles to cell surface
  • Low-density lipoprotein reduction 50–60% on statin
  • Subcutaneous injection every 2 weeks or monthly
  • Cardiovascular outcomes proven

Small interfering RNA

Inclisiran

  • Silences proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid in hepatocytes
  • Prevents protein from being made at all
  • Low-density lipoprotein reduction 50–55% on statin
  • Subcutaneous injection twice yearly
  • Outcomes data pending

Sequential Add-On Framework — How to Build to Target

Step 1

Optimize Statin

High-intensity statin as baseline for all very high-risk patients

→

Step 2

Add Ezetimibe

If LDL target not met: inexpensive, generic, proven, oral, no interactions

→

Step 3

Add PCSK9 Inhibitor

If target still not met: very potent, expensive, injection, prior authorization required

Triple Therapy Effect

High-intensity statin plus ezetimibe plus a proprotein convertase subtilisin/kexin type 9 inhibitor reduces low-density lipoprotein cholesterol 70 to 85 percent from untreated baseline, achieving levels of 20 to 30 mg/dL in most patients. Used in familial hypercholesterolemia, recurrent atherosclerotic cardiovascular disease, and very high baseline low-density lipoprotein after acute coronary syndrome.

Agent Comparison

Feature Ezetimibe Evolocumab / Alirocumab Inclisiran
Mechanism Niemann-Pick C1-Like 1 inhibition Monoclonal antibody blocks PCSK9 protein Small interfering RNA silences PCSK9 mRNA
LDL reduction 18–25% added to statin 50–60% added to statin 50–55% added to statin
Dosing Oral daily Injection every 2 weeks or monthly Injection twice yearly
CV outcomes Proven Proven Pending
Cost Low (generic) High High